Fenster schließen  |  Fenster drucken


CV Therapeutics falls; biotechs mixed

By Ted Griffith, CBS.MarketWatch.com
Last Update: 9:45 AM ET Dec. 8, 2003

BOSTON (CBS.MW) -- Biotechnology stocks were mixed in early trading Monday, with shares of CV Therapeutics tumbling ahead of a crucial regulatory review.

The Amex Biotechnology Index (BTK: news, chart, profile) dipped 0.3 percent, while the Nasdaq Biotechnology Index (NBI: news, chart, profile) edged up 0.3 percent.

CV Therapeutics (CVTX: news, chart, profile) plunged $2.80, or 16.7 percent, to $13.96. A Food and Drug Administration advisory panel on Tuesday is expected to make a recommendation on whether CV Therapeutics` experimental angina treatment, Ranexa, should be approved. The FDA typically follows the recommendations of its advisory panels.

Among the leading gainers, shares of American Pharmaceutical Partners (APPX: news, chart, profile) jumped $1.65 to $37.15. The drugmaker late Friday said its breast cancer therapy produced encouraging results in late-stage patient testing.

Ted Griffith is a reporter for CBS.MarketWatch.com
aus der Diskussion: +++ CV Therapeutics Inc (CVTX) - Kurssturz +++
Autor (Datum des Eintrages): kosto1929  (08.12.03 16:36:26)
Beitrag: 4 von 470 (ID:11549326)
Alle Angaben ohne Gewähr © wallstreet:online